Acquisitions And Revenue GrowthKnight Therapeutics' acquisitions, particularly Paladin and Sumitomo, have contributed positively to revenue growth.
EarningsKnight reported third-quarter results, handily beating estimates.
Financial GuidanceThe company increased its financial guidance to $430M to $440M, suggesting confidence in future performance.